1,829 research outputs found

    Inhibition of Cholinesterases by the Oximes P2AM and Toxogonin

    Get PDF
    The reversible inhibition of electric eel acetylcholinesterase (EC 3.1.1.7) by P2AM (2-(hydroxyimino)methyl-1-methyl-pyridinium chloride) and Toxogonin (1,1\u27-[oxybis(methylene)] bis(4-(hydroxyimino) methyl-pyridinium) dichloride) was studied using ac.etylthiocholine as substrate. Two techniques were applied for measuring acetylthiocholine hydrolysis, the conventional spectrophotometric and the stopped-flow (at 25 °c in 100 mM phosphate buffer pH = 7.4). The correlation between the degree of inhibition, and acetylthiocholine and oxime concentrations fits a theoretical model which postulates that the substrate and the inhibitor bind to two sites on the enzyme: the catalytic site and an allosteric, substrate-inhibition, site. The calculated dissociation constants for the two sites are: 0.13 and 0.76 mM for P2AM, and 0.16 and 2.0 mM for Toxogonin. The suggested model is an alternative to the hypothesis that two types of binding occur within the catalytic site. Horse serum cholinesterase and bovine erythrocyte acetylcholinesterase are also inhibited by P2AM and Toxogonin to about the same degree as the electric eel enzyme. Acetylthiocholine reacts with P2AM and Toxogonin; assuming that the reaction is bimolecular the corresponding rate constants are 13.4 and 22.4 M-1 min-

    Inhibition of Cholinesterases by the Oximes P2AM and Toxogonin

    Get PDF
    The reversible inhibition of electric eel acetylcholinesterase (EC 3.1.1.7) by P2AM (2-(hydroxyimino)methyl-1-methyl-pyridinium chloride) and Toxogonin (1,1\u27-[oxybis(methylene)] bis(4-(hydroxyimino) methyl-pyridinium) dichloride) was studied using ac.etylthiocholine as substrate. Two techniques were applied for measuring acetylthiocholine hydrolysis, the conventional spectrophotometric and the stopped-flow (at 25 °c in 100 mM phosphate buffer pH = 7.4). The correlation between the degree of inhibition, and acetylthiocholine and oxime concentrations fits a theoretical model which postulates that the substrate and the inhibitor bind to two sites on the enzyme: the catalytic site and an allosteric, substrate-inhibition, site. The calculated dissociation constants for the two sites are: 0.13 and 0.76 mM for P2AM, and 0.16 and 2.0 mM for Toxogonin. The suggested model is an alternative to the hypothesis that two types of binding occur within the catalytic site. Horse serum cholinesterase and bovine erythrocyte acetylcholinesterase are also inhibited by P2AM and Toxogonin to about the same degree as the electric eel enzyme. Acetylthiocholine reacts with P2AM and Toxogonin; assuming that the reaction is bimolecular the corresponding rate constants are 13.4 and 22.4 M-1 min-

    Refinement of primary Si in hypereutectic Al-Si alloys by intensive melt shearing

    Get PDF
    Hypereutectic Al-Si based alloys are gaining popularity for applications where a combination of light weight and high wear resistance is required. The high wear resistance arising from the hard primary Si particles comes at the price of extremely poor machine tool life. To minimize machining problems while exploiting outstanding wear resistance, the primary Si particles must be controlled to a uniform small size and uniform spatial distribution. The current industrial means of refining primary Si chemically by the addition of phosphorous suffers from a number of problems. In the present paper an alternative, physical means of refining primary Si by intensive shearing of the melt prior to casting is investigated. Al-15wt%Si alloy has been solidified under varying casting conditions (cooling rate) and the resulting microstructures have been studied using microscopy and quantitative image analysis. Primary Si particles were finer, more compact in shape and more numerous with increasing cooling rate. Intensive melt shearing led to greater refinement and more enhanced nucleation of primary Si than was achieved by adding phosphorous. The mechanism of enhanced nucleation is discussed.EPSRC (grant EP/H026177/1)

    The effects of combined magnesium and zinc supplementation on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease

    Get PDF
    Background: The present research aimed to analyze the impacts of magnesium and zinc supplements on glycemic control, serum lipids, and biomarkers of oxidative stress and inflammation in patients suffering from coronary heart disease (CHD) and type 2 diabetes mellitus (T2DM). Methods: According to the research design, a randomized, double-blind, placebo-controlled trial has been implemented on 60 subjects suffering from CHD and T2DM. Therefore, participants have been randomly divided into 2 groups for taking placebo (n = 30) or 250 mg magnesium oxide plus 150 mg zinc sulfate (n = 30) for 12 weeks. Results: Magnesium and zinc significantly decreased fasting plasma glucose (FPG) (β - 9.44 mg/dL, 95 CI, - 18.30, - 0.57; P = 0.03) and insulin levels (β - 1.37 μIU/mL, 95 CI, - 2.57, - 0.18; P = 0.02). Moreover, HDL-cholesterol levels significantly enhanced (β 2.09 mg/dL, 95 CI, 0.05, 4.13; P = 0.04) in comparison to the placebo. There was an association between magnesium and zinc intake, and a significant decrease of C-reactive protein (CRP) (β - 0.85 mg/L, 95 CI, - 1.26, - 0.45; P < 0.001), a significant increase in total nitrite (β 5.13 μmol/L, 95 CI, 1.85, 8.41; P = 0.003) and total antioxidant capacity (TAC) (β 43.44 mmol/L, 95 CI, 3.39, 83.50; P = 0.03) when compared with placebo. Furthermore, magnesium and zinc significantly reduced the Beck Depression Inventory index (BDI) (β - 1.66; 95 CI, - 3.32, - 0.009; P = 0.04) and Beck Anxiety Inventory (BAI) (β - 1.30; 95 CI, - 2.43, - 0.16; P = 0.02) when compared with the placebo. Conclusions: In patients with T2DM and CHD, the 12-week intake of magnesium plus zinc had beneficial effects on FPG, HDL-cholesterol, CRP, insulin, total nitrite, TAC levels, and BDI and BAI score. This suggests that magnesium and zinc co-supplementation may be beneficial for patients with T2DM and CHD. Further studies on more patients and lasting longer are needed to determine the safety of magnesium and zinc co-supplementation. Trial registration: Current Controlled Trials http://www.irct.ir: IRCT20130211012438N31 at 11 May 2019 of registration. This study retrospectively registered. © 2020 The Author(s)

    Mehanizam toksičnosti i detoksikacije organofosfornih spojeva s naglaskom na istraživanja u Hrvatskoj

    Get PDF
    This review comprises studies on the mechanisms of toxicity and detoxication of organophosphorus (OP) compounds done in Croatia in different research areas. One area is the synthesis of antidotes against OP poisoning and their in vivo testing in experimental animals. In vitro studies included in this review focus on the mechanisms of reversible inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), protection of cholinesterases from inhibition by OPs, and reactivation of phosphylated cholinesterases. The third area comprises distribution profiles of BChE and paraoxonase (PON) phenotypes in selected population groups and the detection of OPs and metabolites in humans. Finally, methods are described for the detection of OP compounds in human blood and other media by means of cholinesterase inhibitionPrikazana su istraživanja vođena u Hrvatskoj na različitim područjima mehanizma toksičnosti i detoksikacije organofosfornih (OP) spojeva. Jedno je područje sinteza antidota protiv otrovanja OP spojevima i testiranje in vivo antidota na eksperimentalnim životinjama. Istraživanja in vitro odnose se na mehanizam reverzibilne inhibicije acetilkolinesteraze (AChE) i buturilkolinesteraze (BChE), zaštitu kolinesteraza od inhibicije OP spojevima te reaktivaciju fosfiliranih kolinesteraza. Treće je područje distribucija fenotipova BChE i paraoksonaze (PON) u odabranim populacijama te detekcija OP spojeva i njihovih metabolita u ljudima. Na kraju su opisane metode detekcije OP spojeva u ljudskoj krvi i drugim medijima koje se osnivaju na inhibiciji kolinesteraza

    The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: A systematic review and meta-analysis of randomized controlled trials

    Get PDF
    Introduction: So far, no study has summarized the findings on the effects of berberine intake on anthropometric parameters, C-reactive protein (CRP) and liver enzymes. This systematic review and meta-analysis were done based upon randomized controlled trials (RCTs) to analyze the effects of berberine on anthropometric parameters, CRP and liver enzymes. Method: Following databases were searched for eligible studies published from inception to 30 July 2019: MEDLINE, EMBASE, Web of Science, Cochrane Library, PubMed and Google scholar. Necessary data were extracted. Data were pooled by the inverse variance method and expressed as mean difference with 95 Confidence Intervals (95 CI). Result: 12 studies were included. Berberine treatment moderately but significantly decreased body weight (WMD = �2.07 kg, 95 CI -3.09, �1.05, P &lt; 0.001), body mass index (BMI) (WMD = �0.47 kg/m2, 95 CI -0.70, �0.23, P &lt; 0.001), waist circumference (WC) (WMD = �1.08 cm, 95 CI -1.97, �0.19, P = 0.018) and C-reactive protein (CRP) concentrations (WMD = �0.42 mg/L, 95 CI -0.82, �0.03, P = 0.034). However, berberine intake did not affect liver enzymes, including alanine aminotransferase (ALT) (WMD = �1.66 I/U, 95 CI -3.98, 0.65, P = 0.160) and aspartate aminotransferase (AST) (WMD = �0.87 I/U, 95 CI -2.56, 0.82, P = 0.311). Conclusion: This meta-analysis found a significant reduction of body weight, BMI, WC and CRP levels associated with berberine intake which may have played an indirect role in improved clinical symptoms in diseases with metabolic disorders. Berberine administration had no significant effect on ALT and AST levels. © 2020 European Society for Clinical Nutrition and Metabolis
    corecore